Valneva SE (LON: 0OB3)
London
· Delayed Price · Currency is GBP · Price in EUR
2.288
+0.116 (5.34%)
Jan 23, 2025, 1:42 PM BST
Valneva SE Revenue
Valneva SE had revenue of 45.82M EUR in the quarter ending September 30, 2024, with 20.36% growth. This brings the company's revenue in the last twelve months to 158.54M, down -28.98% year-over-year. In the year 2023, Valneva SE had annual revenue of 153.71M, down -57.46%.
Revenue (ttm)
158.54M EUR
Revenue Growth
-28.98%
P/S Ratio
n/a
Revenue / Employee
234.52K EUR
Employees
676
Market Cap
296.87M GBP
Revenue Chart
* This company reports financials in EUR.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 153.71M | -207.59M | -57.46% |
Dec 31, 2022 | 361.30M | 13.22M | 3.80% |
Dec 31, 2021 | 348.09M | 237.76M | 215.52% |
Dec 31, 2020 | 110.32M | -15.88M | -12.58% |
Dec 31, 2019 | 126.20M | 13.16M | 11.64% |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Dec 31, 2014 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
AstraZeneca | 38.20B |
GSK plc | 31.31B |
Haleon | 11.24B |
Smith & Nephew | 4.46B |
ConvaTec Group | 1.74B |
Hikma Pharmaceuticals | 2.39B |
HUTCHMED (China) | 483.31M |
Oxford Nanopore Technologies | 167.75M |
Valneva SE News
- 21 hours ago - Valneva Reports Positive Phase 2 Results in Children for its Chikungunya Vaccine and Announces Phase 3 Dose Decision - GlobeNewsWire
- 1 day ago - Valneva Vaccine Shows Sustained Immune Response In Adolescents One Year After Single Shot - Benzinga
- 1 day ago - Valneva Vaccine Shows Sustained Immune Response In Adolescents One Year After Single Shot - Benzinga
- 2 days ago - Valneva gains after new Phase 3 data for chikungunya vaccine in adolescents - Seeking Alpha
- 2 days ago - Valneva Reports High Sustained Immune Response in Adolescents One Year After Single Vaccination with its Chikungunya Vaccine - GlobeNewsWire
- 16 days ago - Valneva to Meet with Investors during the J.P. Morgan Healthcare Conference - GlobeNewsWire
- 5 weeks ago - Valneva Successfully Expands Access to Asia for its Chikungunya Vaccine with Serum Institute of India - GlobeNewsWire
- 7 weeks ago - Valneva Announces Peer-Reviewed Publication on the Global Health and Economic Burden of Chikungunya in The British Medical Journal - GlobeNewsWire